reviewing;'Capricor Therapeutics, Inc. (CAPR)';suffering from acute respiratory distress syndrome (ARDS) re; may $10+ today ? a BEAST starts 04-29-2020; big time play now,huge reporting; U.S. FDA Approves Company’s Expanded [04-29-2020] Access Protocol to Treat Additional Patients
LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases.
Over the course of one month, six critically ill COVID-19 patients, all suffering from acute respiratory distress syndrome (ARDS) and five of whom were on mechanical ventilatory support, were safely treated with CAP-1002. Of the six patients treated, four of them have been discharged.
Following a review of the available data, the U.S. Food and Drug Administration (FDA) approved the Company’s expanded access protocol to treat up to 20 additional COVID-19 patients.
There is also a randomized, placebo-controlled trial planned to treat patients with moderate and severe disease which is intended to be funded by non-equity capital.
In the compassionate care cases, five male patients and one female patient (between ages 19 and 75)
suffering from COVID-19 received IV infusions of 150 million allogeneic cardiosphere-derived cells (CAP-1002)..........
Market Data 
Markets 
AI
